Kyron.bio
French tech company | Builders Republic
About
Biotech that engineers the sugar molecules (glycans) coating therapeutic antibodies — precisely controlling glycosylation to make biologic drugs for cancer and autoimmune diseases more effective and safer — licensing its platform to pharma partners to glycoengineer their own antibodies.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2022
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 5.5 M€ raised since 2020
Funding rounds
- Series A — 2025